SNDT WOMEN'S UNIVERSITY

BMK Knowledge Resource Centre

Vithaldas Vidyavihar, Juhu Tara Road,
Santacruz (West) Mumbai - 400049

DEVELOPMENT AND EVALUATION OF PHARMACEUTICALLY EQUIVALENT LEVOSALBUTAMOL DRY POWDER INHALER WITH INCREASED IN VITRO DEPOSITION (Record no. 131150)

MARC details
000 -LEADER
fixed length control field 02249nam a2200157 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250215b |||||||| |||| 00| 0 eng d
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Item number P. 44-520
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Suraj L. Dongare
245 ## - TITLE STATEMENT
Title DEVELOPMENT AND EVALUATION OF PHARMACEUTICALLY EQUIVALENT LEVOSALBUTAMOL DRY POWDER INHALER WITH INCREASED IN VITRO DEPOSITION
300 ## - PHYSICAL DESCRIPTION
Extent P. 44-520
520 ## - SUMMARY, ETC.
Summary, etc. biblio.abstract The advancement and assessment of an efficient and safe dry powder inhaler formulation for levosalbutamol are critical for optimizing its therapeutic potential in managing chronic obstructive pulmonary disease (COPD). This study aims to provide an overview of the development process and evaluation outcomes of a levosalbutamol dry powder inhaler, including formulation development, physicochemical characterization and in vitro performance assessment. It employed a stepwise approach to develop and evaluate the inhaler. Initially, different excipients (Respitose®SV010, Respitose®ML006, Respitose®SV003, Lactohale LH100, Lactohale LH300) and particle size distributions were evaluated to optimize the formulation. Physicochemical characterization, such as particle size, shape and density were conducted using appropriate techniques. In vitro performance assessments, together with fine particle fractions, emitted dose and aerodynamic particle size distribution was determined using validated methods. The formulation development process resulted in an optimized levosalbutamol dry powder inhaler with desirable physicochemical properties, including uniform particle size distribution and suitable density for effective inhalation. In vitro assessments demonstrated favourable aerodynamic characteristics, with a high emitted dose and significant fine particle fraction, indicating efficient lung deposition and therapeutic efficacy. These findings support the potential of the levosalbutamol dry powder inhaler as an effective treatment option for respiratory conditions such as asthma and COPD.
654 ## - SUBJECT ADDED ENTRY--FACETED TOPICAL TERMS
Subject <a href="Levosalbutamol">Levosalbutamol</a>
-- <a href="dry powder inhaler ">dry powder inhaler </a>
-- <a href="formulation development ">formulation development </a>
-- <a href="physicochemical characterization ">physicochemical characterization </a>
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Minal R. Narkhede
773 0# - HOST ITEM ENTRY
Host Biblionumber 125265
Host Itemnumber 109908
Place, publisher, and date of publication Mumbai Indian Drugs Manufacturer's Association
Title Indian Drugs
International Standard Serial Number 0019-462X
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Koha normalized classification for sorting Not for loan Location (home branch) Sublocation or collection (holding branch) Date acquired Koha issues (times borrowed) Koha full call number Piece designation (barcode) Koha date last seen Price effective from Koha item type
    Dewey Decimal Classification   P___44520   SNDT Juhu SNDT Juhu 15/02/2025   P. 44-520 JP287.4 15/02/2025 15/02/2025 Journal Article